On CNBC’s “Mad Money Lightning Round,” Jim Cramer said he can’t own Apple Hospitality REIT, Inc. (NYSE:APLE) if rates are going to 6%. “You’re going to end up losing money if you buy that stock,” he added.
On earnings, Apple Hospitality REIT said it plans to report third-quarter results after the closing bell on Thursday, Nov. 5.
When asked about Corteva, Inc. (NYSE:CTVA), he said, “There is absolutely no reason you would want to own this one over Vylor (NYSE:VYLR).”
On Oct. 1, Corteva completed the spin-off of its seed and genetics business into Vylor.
Cramer said yes to Jazz Pharmaceuticals plc (NASDAQ:JAZZ), adding, “You’re starting to go into a very speculative situation where they actually do make money, though.”
RBC Capital analyst Leonid Timashev maintained an Outperform rating on Jazz Pharmaceuticals on Oct. 8 and cut the price target from $299 to $296.
“We’re going to take a harder look at Onto (NYSE:ONTO) because it’s another one of these companies that’s in process control solutions, and they’re all really hard to understand,” Cramer said.
RBC Capital analyst Srini Pajjuri initiated coverage of Onto Innovation on Oct. 2 with an Outperform rating and a price target of $400.
Cramer said, “I read today [on Friday] a very informative piece about how EchoStar (NASDAQ:ECHO) could get a bid from SpaceX (NASDAQ:SPCX), and it was very compelling. I’ve not liked the stock, but I certainly cannot be oblivious to that takeover."
Morgan Stanley analyst Sean Diffley assumed EchoStar with an Overweight rating on Sept. 14 and set a price target of $134.
Price Action
- Corteva shares fell 3.7% to settle at $13.24 on Friday.
- Onto Innovation shares gained 0.6% to close at $294.53 during the session.
- Apple Hospitality rose 0.6% to settle at $16.31 on Friday.
- EchoStar shares gained 1.6% to close at $94.84 during the session.
- Jazz Pharmaceuticals shares fell 1.8% to settle at $218.42.
See More: Top Value Stocks
Photo via Shutterstock